Materialise (MTLS) 주식 개요
Materialise NV는 미주, 유럽, 아프리카 및 아시아 태평양 지역에서 적층 제조 및 의료 소프트웨어 도구와 3D 프린팅 서비스를 제공합니다. 자세히 보기
강점
위험 분석
우리의 위험 점검에서 MTLS에 대한 위험이 감지되지 않았습니다.
MTLS Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Materialise NV 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | US$7.43 |
| 52주 최고가 | US$7.67 |
| 52주 최저가 | US$4.78 |
| 베타 | 1.36 |
| 1개월 변동 | 8.15% |
| 3개월 변동 | 11.56% |
| 1년 변동 | 42.88% |
| 3년 변동 | 22.20% |
| 5년 변동 | -68.17% |
| IPO 이후 변동 | -37.56% |
최근 뉴스 및 업데이트
내러티브 업데이트 • Sep 03
MTLS: Reaffirmed 2026 Guidance Will Support Higher Profitability Expectations
Analysts have modestly raised their price target on Materialise to about $8.06 from about $6.81, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E multiples. What's in the News for Materialise Materialise NV recorded impairment charges of €689,000 in the second quarter of 2026 related to tangible and intangible assets of RapidFit NV and Eyewear, following the transfer of these assets to their respective management teams.Seeking Alpha • Aug 31
Materialise: A High-Margin Medical Business Hiding In Plain Sight
Summary Materialise’s Medical continues to deliver double-digit growth and strong margins and is increasingly underpinning the company’s value. The Manufacturing segment is recovering, with aerospace strength offsetting weak prototyping demand and creating significant potential for margin expansion. Software is now an uncertainty, as recurring revenue growth has stalled despite Materialise's transition toward subscriptions and the introduction of new CO-AM products. The valuation remains attractive if Materialise can achieve even modest revenue growth and margin expansion over the next few years. Read the full article on Seeking Alpha분석 기사 • Aug 30
Materialise NV (NASDAQ:MTLS) Released Earnings Last Week And Analysts Lifted Their Price Target To US$8.92
It's been a good week for Materialise NV ( NASDAQ:MTLS ) shareholders, because the company has just released its latest...Recent updates
내러티브 업데이트 • Sep 03
MTLS: Reaffirmed 2026 Guidance Will Support Higher Profitability Expectations
Analysts have modestly raised their price target on Materialise to about $8.06 from about $6.81, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E multiples. What's in the News for Materialise Materialise NV recorded impairment charges of €689,000 in the second quarter of 2026 related to tangible and intangible assets of RapidFit NV and Eyewear, following the transfer of these assets to their respective management teams.Seeking Alpha • Aug 31
Materialise: A High-Margin Medical Business Hiding In Plain Sight
Summary Materialise’s Medical continues to deliver double-digit growth and strong margins and is increasingly underpinning the company’s value. The Manufacturing segment is recovering, with aerospace strength offsetting weak prototyping demand and creating significant potential for margin expansion. Software is now an uncertainty, as recurring revenue growth has stalled despite Materialise's transition toward subscriptions and the introduction of new CO-AM products. The valuation remains attractive if Materialise can achieve even modest revenue growth and margin expansion over the next few years. Read the full article on Seeking Alpha분석 기사 • Aug 30
Materialise NV (NASDAQ:MTLS) Released Earnings Last Week And Analysts Lifted Their Price Target To US$8.92
It's been a good week for Materialise NV ( NASDAQ:MTLS ) shareholders, because the company has just released its latest...
새로운 내러티브 • Jun 01
Medical And Software Expansion Will Drive Stronger Margins And Earnings Durability
Catalysts About Materialise Materialise provides 3D printing software and services, with a particular focus on medical applications and industrial manufacturing. What are the underlying business or industry changes driving this perspective?새로운 내러티브 • May 17
Cloud Software And Medical Constraints Will Pressure 3D Printing Adoption Yet Offer Gradual Upside
Catalysts About Materialise Materialise provides software and manufacturing solutions for 3D printing, with a particular focus on medical applications, industrial production and related services. What are the underlying business or industry changes driving this perspective?분석 기사 • Nov 05
Materialise's (NASDAQ:MTLS) Sluggish Earnings Might Be Just The Beginning Of Its Problems
The market rallied behind Materialise NV's ( NASDAQ:MTLS ) stock, leading do a rise in the share price after its recent...분석 기사 • Oct 06
Materialise NV's (NASDAQ:MTLS) P/E Is On The Mark
With a price-to-earnings (or "P/E") ratio of 54.9x Materialise NV ( NASDAQ:MTLS ) may be sending very bearish signals...분석 기사 • Jul 27
Analyst Estimates: Here's What Brokers Think Of Materialise NV (NASDAQ:MTLS) After Its Second-Quarter Report
Shareholders might have noticed that Materialise NV ( NASDAQ:MTLS ) filed its quarterly result this time last week. The...분석 기사 • Jul 25
Materialise (NASDAQ:MTLS) Is Looking To Continue Growing Its Returns On Capital
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...분석 기사 • May 04
After Leaping 28% Materialise NV (NASDAQ:MTLS) Shares Are Not Flying Under The Radar
Those holding Materialise NV ( NASDAQ:MTLS ) shares would be relieved that the share price has rebounded 28% in the...Seeking Alpha • Feb 24
Materialise: Manufacturing Headwinds Are A Distraction
Summary Materialise's share price dropped significantly after the company reported poor Q4 earnings, which were driven by European automotive market weakness. Despite recent challenges, Materialise's Medical segment continues to perform well and the transition of the Software segment to a subscription model is progressing. The Medical and Software segments are Materialise's primary value drivers and more than justify the company's current valuation. Issues with the Manufacturing segment may need to be resolved before the stock moves higher though. Read the full article on Seeking Alpha분석 기사 • Feb 13
Materialise NV's (NASDAQ:MTLS) P/E Is Still On The Mark Following 26% Share Price Bounce
Materialise NV ( NASDAQ:MTLS ) shareholders have had their patience rewarded with a 26% share price jump in the last...
새로운 내러티브 • Feb 09
Launch Of Mimics Flow And ACTech Expansion Will Advance Personalized Medicine
Focus on personalized medical solutions and enhanced platforms could drive revenue growth and improve operational efficiencies and net margins.분석 기사 • Jan 31
Materialise NV (NASDAQ:MTLS) Shares Could Be 28% Above Their Intrinsic Value Estimate
Key Insights Using the 2 Stage Free Cash Flow to Equity, Materialise fair value estimate is US$6.77 Materialise is...분석 기사 • Jan 07
These 4 Measures Indicate That Materialise (NASDAQ:MTLS) Is Using Debt Safely
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...분석 기사 • Nov 07
Materialise NV's (NASDAQ:MTLS) 27% Jump Shows Its Popularity With Investors
Materialise NV ( NASDAQ:MTLS ) shares have had a really impressive month, gaining 27% after a shaky period beforehand...Seeking Alpha • Nov 04
Materialise: Strong Q3 Results Despite Ongoing Market Headwinds
Summary Materialise continues to grow on the back of its Medical segment, which is expanding at a rapid pace. Materialise's margins will continue to improve going forward, driven by a combination of revenue mix and economies of scale. The ACTech plant expansion will provide a material tailwind in 2025, although disruptions wrought by its startup are likely to negatively impact fourth quarter revenue. Despite the stock moving higher in recent weeks, Materialise remains deeply undervalued. Read the full article on Seeking Alpha분석 기사 • Nov 01
Materialise's (NASDAQ:MTLS) Strong Earnings Are Of Good Quality
Materialise NV ( NASDAQ:MTLS ) recently posted some strong earnings, and the market responded positively. We did some...Seeking Alpha • Oct 25
Materialise: Medical Business Unit Is The Hidden Value
Summary Materialise NV is a Belgian additive manufacturing company, showing a 14.18% CAGR in its Medical segment from FY18 to FY23. Despite mixed results in other segments, Materialise maintains profitability with positive FCF and a strong balance sheet, supported by €63 million in net cash. The company's strategic positioning in high-value sectors and steady growth, combined with a net cash position and positive FCF, highlight its upside potential. DCF analysis suggests Materialise is undervalued by 35-40%, justifying a "buy" rating due to its innovative edge and expanding market in healthcare. Read the full article on Seeking Alpha분석 기사 • Oct 25
Is There Now An Opportunity In Materialise NV (NASDAQ:MTLS)?
While Materialise NV ( NASDAQ:MTLS ) might not have the largest market cap around , it led the NASDAQGS gainers with a...Seeking Alpha • Aug 01
Materialise Stock: Nearing An Inflection Point (Rating Upgrade)
Summary Materialise NV continues to face headwinds from soft prototyping demand and muted 3D printer sales. Despite this, Materialise reported solid Q2 results, with growth improving sharply. Recent acquisitions, new software launches, and expanded manufacturing capacity are expected to drive growth going forward. While Materialise's share price has moved higher recently, the prospect of solid growth and significantly higher margins are not priced into the stock. Read the full article on Seeking Alpha분석 기사 • Aug 01
The Return Trends At Materialise (NASDAQ:MTLS) Look Promising
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...Seeking Alpha • Apr 26
Materialise Q1: Progress Against Headwinds
Summary Materialise NV faces a challenging demand environment and is transitioning to a cloud-based SaaS business model, impacting its financial performance. The software business is progressing slowly, while the medical business continues to perform well. The manufacturing business is struggling, but the startup of the expanded ACTech facility later in the year could change this. Macro headwinds and ongoing investments probably limit near-term upside. Longer term, Materialise appears deeply undervalued. Read the full article on Seeking Alpha분석 기사 • Apr 19
Materialise's (NASDAQ:MTLS) Strong Earnings Are Of Good Quality
Materialise NV ( NASDAQ:MTLS ) just reported healthy earnings but the stock price didn't move much. Investors are...Seeking Alpha • Feb 26
Materialise: Upside From A Transition To Profitability
Summary The demand environment continues to weigh on Materialise's business, although the Medical segment remains a standout, with strong growth and improving margins. The adoption of robotics in joint replacement surgeries poses a threat to Materialise's medical business, though. Investments in the CO-AM platform and the ACTech facility expansion should begin to pay off in 2024, supporting growth and Materialise's competitive position. Given Materialise's relatively low valuation and the potential for solid growth and improving margins, Materialise's stock should do well over the next 1-2 years. Read the full article on Seeking Alpha분석 기사 • Feb 23
Does Materialise (NASDAQ:MTLS) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Seeking Alpha • Jan 31
Materialise NV: Consolidation And New Developments To Emerge As A Rising Star In The Additive Manufacturing Industry
Summary Materialise NV currently exhibits better growth, margins and fundamentals than its main competitors, positioning itself well in an industry that is estimated to grow at a CAGR of 16% until 2032; The medical business unit (c.a. 38.5% of total revenues in 9M23) continues to achieve double-digit growth, with the appointment of the new CEO to focus strongly on this segment; Both the analysis of multiples and DCF here presented show that the current share valuation is 40-45% below its fundamental value. Read the full article on Seeking Alpha분석 기사 • Jun 14
Here's Why Materialise (NASDAQ:MTLS) Can Manage Its Debt Responsibly
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...분석 기사 • May 23
Returns On Capital At Materialise (NASDAQ:MTLS) Paint A Concerning Picture
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Ideally, a business...주주 수익률
| MTLS | US Software | US 시장 | |
|---|---|---|---|
| 7D | 5.7% | -0.7% | -0.2% |
| 1Y | 42.9% | -9.0% | 14.8% |
수익률 대 산업: MTLS은 지난 1년 동안 -9%의 수익을 기록한 US Software 산업보다 더 좋은 성과를 냈습니다.
수익률 대 시장: MTLS은 지난 1년 동안 14.8%를 기록한 US 시장보다 더 좋은 성과를 냈습니다.
주가 변동성
| MTLS volatility | |
|---|---|
| MTLS Average Weekly Movement | 5.6% |
| Software Industry Average Movement | 9.2% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 2.9% |
안정적인 주가: MTLS는 지난 3개월 동안 US 시장에 비해 주가 변동성이 크지 않았습니다.
시간에 따른 변동성: MTLS의 주간 변동성(6%)은 지난 1년 동안 안정적이었습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 1990 | 2,556 | Brigitte de Vet-Veithen | www.materialise.com |
Materialise NV는 미주, 유럽, 아프리카 및 아시아 태평양 지역에서 적층 제조 및 의료 소프트웨어 도구와 3D 프린팅 서비스를 제공합니다. 이 회사는 세 가지 부문으로 운영됩니다: 머티리얼라이즈 소프트웨어, 머티리얼라이즈 메디컬, 머티리얼라이즈 매뉴팩처링입니다. 머티리얼라이즈 소프트웨어 부문은 3D 프린터의 기능을 활성화하고 향상시키는 프로그램과 플랫폼을 통해 독점 소프트웨어를 제공하고 프린팅 작업을 지원합니다.
Materialise NV 기초 지표 요약
| MTLS 기초 통계 | |
|---|---|
| 시가총액 | US$431.64m |
| 순이익 (TTM) | US$15.33m |
| 매출 (TTM) | US$316.73m |
28.0x
주가수익비율(P/E)1.4x
주가매출비율(P/S)MTLS는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| MTLS 손익계산서 (TTM) | |
|---|---|
| 매출 | €272.77m |
| 매출원가 | €116.66m |
| 총이익 | €156.12m |
| 기타 비용 | €142.91m |
| 순이익 | €13.21m |
최근 보고된 실적
Jun 30, 2026
다음 실적 발표일
Oct 28, 2026
| 주당순이익(EPS) | 0.23 |
| 총이익률 | 57.23% |
| 순이익률 | 4.84% |
| 부채/자본 비율 | 20.9% |
MTLS의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/09/10 00:52 |
| 종가 | 2026/09/10 00:00 |
| 수익 | 2026/06/30 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Materialise NV는 11명의 분석가가 다루고 있습니다. 이 중 3명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| John Baliotti | Brean Capital Historical (Janney Montgomery) |
| Robert Burleson | Canaccord Genuity |
| Troy Jensen | Cantor Fitzgerald & Co. |